What is ProteoGenex?
ProteoGenex operates as a critical infrastructure provider within the life sciences ecosystem, specializing in the procurement and distribution of high-quality human biological specimens. The company's portfolio includes a diverse array of formats, such as Fresh Frozen, Formalin-Fixed, Paraffin-Embedded (FFPE), and Tissue Microarray (TMA) samples. By providing essential biological materials—including blood products, RNA, DNA, and biofluids—the firm serves as a vital partner for both academic institutions and commercial pharmaceutical entities.
The company distinguishes itself through a rigorous commitment to ethical collection standards and stringent quality control protocols. By facilitating access to samples from both normal and diseased donors, ProteoGenex enables researchers to conduct precise, data-driven investigations that are foundational to modern drug discovery and clinical diagnostics. Their market position is defined by a unique combination of logistical expertise and deep clinical insight, allowing them to offer bespoke collection services tailored to specific research objectives.
How much funding has ProteoGenex raised?
ProteoGenex has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in ProteoGenex
PPP
Public-Private Partnership
What's next for ProteoGenex?
With the successful closure of this late-stage funding, ProteoGenex is poised to transition into a phase of aggressive market expansion and technological integration. The strategic deployment of these funds will likely focus on scaling their biobanking infrastructure and enhancing their digital clinical data platforms to meet the increasing demand for high-fidelity research materials. As the life sciences industry shifts toward more personalized medicine, the company's ability to provide granular, ethically sourced clinical information will be a primary driver of its future competitive advantage.
Looking ahead, ProteoGenex is expected to leverage this capital to strengthen its global supply chain and potentially explore new therapeutic areas. By deepening its relationships with clinical networks and investing in advanced analytical tools, the firm is set to solidify its role as an indispensable node in the global research and development value chain.
